{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:31:26Z","timestamp":1787056286964,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100020363","name":"Institute for Information Industry, Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC-111-2314-B-037-094 -MY3"],"award-info":[{"award-number":["NSTC-111-2314-B-037-094 -MY3"]}],"id":[{"id":"10.13039\/501100020363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020363","name":"Institute for Information Industry, Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC-113-2314-B-037-042-MY3"],"award-info":[{"award-number":["NSTC-113-2314-B-037-042-MY3"]}],"id":[{"id":"10.13039\/501100020363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-DK(A)113013"],"award-info":[{"award-number":["KMU-DK(A)113013"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-DK(B)114002-2"],"award-info":[{"award-number":["KMU-DK(B)114002-2"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["NYCUKMU-114-I005"],"award-info":[{"award-number":["NYCUKMU-114-I005"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KAFGH_D_115026"],"award-info":[{"award-number":["KAFGH_D_115026"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KAFGH_D_115052"],"award-info":[{"award-number":["KAFGH_D_115052"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015045","name":"Kaohsiung Armed Forces General Hospital","doi-asserted-by":"publisher","award":["KAFGH_D_113035"],"award-info":[{"award-number":["KAFGH_D_113035"]}],"id":[{"id":"10.13039\/501100015045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015045","name":"Kaohsiung Armed Forces General Hospital","doi-asserted-by":"publisher","award":["KAFGH_D_114034"],"award-info":[{"award-number":["KAFGH_D_114034"]}],"id":[{"id":"10.13039\/501100015045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08293-w","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:37:03Z","timestamp":1779370623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-associated protease-activated anti-CD47 antibody precisely maintains phagocytic ability of macrophages with minimal effect on healthy tissue"],"prefix":"10.1186","volume":"24","author":[{"given":"Yu-Tung","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zih-Yu","family":"Jhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Chi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Lu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6868","authenticated-orcid":false,"given":"Wen-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"7","key":"8293_CR1","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00262-020-02806-2","volume":"70","author":"M Shi","year":"2021","unstructured":"Shi M, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunol Immunother. 2021;70(7):1831\u201340.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"8293_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2016.08.325","volume":"143","author":"RM Brightwell","year":"2016","unstructured":"Brightwell RM, et al. The CD47 don\u2019t eat me signal is highly expressed in human ovarian cancer. Gynecol Oncol. 2016;143(2):393\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8293_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1186\/s12885-022-10114-4","volume":"22","author":"M Votava","year":"2022","unstructured":"Votava M, et al. The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy. BMC Cancer. 2022;22(1):1021.","journal-title":"BMC Cancer"},{"key":"8293_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3389\/fimmu.2017.00404","volume":"8","author":"L Liu","year":"2017","unstructured":"Liu L, et al. Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. Front Immunol. 2017;8:404.","journal-title":"Front Immunol"},{"issue":"3","key":"8293_CR5","first-page":"3249","volume":"18","author":"J Yuan","year":"2019","unstructured":"Yuan J, et al. High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis. Oncol Lett. 2019;18(3):3249\u201355.","journal-title":"Oncol Lett"},{"key":"8293_CR6","doi-asserted-by":"crossref","unstructured":"van Duijn A, van der Burg SH, Scheeren FA. CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity. J Immunother Cancer. 2022;10(7).","DOI":"10.1136\/jitc-2022-004589"},{"key":"8293_CR7","doi-asserted-by":"crossref","unstructured":"Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022;10(11).","DOI":"10.1136\/jitc-2022-005517"},{"key":"8293_CR8","doi-asserted-by":"crossref","unstructured":"Osorio JC, et al. The antitumor activities of anti-CD47 antibodies require Fc-Fc\u03b3R interactions. Cancer Cell. 2023;41(12):2051\u20132065.e6.","DOI":"10.1016\/j.ccell.2023.10.007"},{"issue":"9","key":"8293_CR9","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.7150\/thno.40860","volume":"10","author":"T Hu","year":"2020","unstructured":"Hu T, et al. Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics. 2020;10(9):4056\u201372.","journal-title":"Theranostics"},{"issue":"18","key":"8293_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma. N Engl J Med. 2018;379(18):1711\u201321.","journal-title":"N Engl J Med"},{"key":"8293_CR11","doi-asserted-by":"crossref","unstructured":"Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021;118(29).","DOI":"10.1073\/pnas.2026849118"},{"issue":"3","key":"8293_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","volume":"101","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022;101(3):557\u201369.","journal-title":"Ann Hematol"},{"issue":"2","key":"8293_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00262-021-03010-6","volume":"71","author":"RK Narla","year":"2022","unstructured":"Narla RK, et al. Modulation of CD47-SIRP\u03b1 innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunol Immunother. 2022;71(2):473\u201389.","journal-title":"Cancer Immunol Immunother"},{"key":"8293_CR14","doi-asserted-by":"publisher","first-page":"1356421","DOI":"10.3389\/fcell.2024.1356421","volume":"12","author":"S Kaur","year":"2024","unstructured":"Kaur S, et al. Effects of a humanized CD47 antibody and recombinant SIRP\u03b1 proteins on triple negative breast carcinoma stem cells. Front Cell Dev Biol. 2024;12:1356421.","journal-title":"Front Cell Dev Biol"},{"issue":"5473","key":"8293_CR15","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, et al. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051\u20134.","journal-title":"Science"},{"issue":"3","key":"8293_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/bjc.2017.173","volume":"117","author":"L Barrera","year":"2017","unstructured":"Barrera L, et al. CD47 overexpression is associated with decreased neutrophil apoptosis\/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br J Cancer. 2017;117(3):385\u201397.","journal-title":"Br J Cancer"},{"issue":"9","key":"8293_CR17","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1182\/blood-2004-08-2980","volume":"105","author":"M Olsson","year":"2005","unstructured":"Olsson M, et al. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105(9):3577\u201382.","journal-title":"Blood"},{"issue":"4","key":"8293_CR18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbrc.2006.03.094","volume":"343","author":"T Ishikawa-Sekigami","year":"2006","unstructured":"Ishikawa-Sekigami T, et al. Enhanced phagocytosis of CD47-deficient red blood cells by splenic macrophages requires SHPS-1. Biochem Biophys Res Commun. 2006;343(4):1197\u2013200.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"8293_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271\u201385.","journal-title":"Cell"},{"issue":"12","key":"8293_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 2019;37(12):946\u201353.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8293_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","volume":"23","author":"PS Petrova","year":"2017","unstructured":"Petrova PS, et al. TTI-621 (SIRP\u03b1Fc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017;23(4):1068\u201379.","journal-title":"Clin Cancer Res"},{"key":"8293_CR22","doi-asserted-by":"crossref","unstructured":"Chen SH, et al. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J Immunother Cancer. 2021;9(10).","DOI":"10.1136\/jitc-2021-003464"},{"issue":"15suppl","key":"8293_CR23","doi-asserted-by":"publisher","first-page":"e14016","DOI":"10.1200\/jco.2015.33.15_suppl.e14016","volume":"33","author":"Z Johnson","year":"2015","unstructured":"Johnson Z, et al. Bispecific antibody targeting of CD47\/CD19 to promote enhanced phagocytosis of patient B lymphoma cells. J Clin Oncol. 2015;33(15suppl):e14016\u201314016.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8293_CR24","doi-asserted-by":"publisher","first-page":"2310248","DOI":"10.1080\/19420862.2024.2310248","volume":"16","author":"D Zhu","year":"2024","unstructured":"Zhu D, et al. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin\u2019s lymphoma. MAbs. 2024;16(1):2310248.","journal-title":"MAbs"},{"key":"8293_CR25","doi-asserted-by":"crossref","unstructured":"Grandcl\u00e9ment C, et al. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma. Nat Commun. 2024;15(1):2054.","DOI":"10.1038\/s41467-024-46310-y"},{"key":"8293_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin M, et al. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577.","journal-title":"BMC Cancer"},{"issue":"3","key":"8293_CR27","doi-asserted-by":"publisher","first-page":"e0193601","DOI":"10.1371\/journal.pone.0193601","volume":"13","author":"T Starr","year":"2018","unstructured":"Starr T, et al. The phorbol 12-myristate-13-acetate differentiation protocol is critical to the interaction of THP-1 macrophages with Salmonella Typhimurium. PLoS ONE. 2018;13(3):e0193601.","journal-title":"PLoS ONE"},{"issue":"6","key":"8293_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.chom.2018.04.013","volume":"23","author":"V Sedlyarov","year":"2018","unstructured":"Sedlyarov V, et al. The Bicarbonate Transporter SLC4A7 Plays a Key Role in Macrophage Phagosome Acidification. Cell Host Microbe. 2018;23(6):766\u2013e7745.","journal-title":"Cell Host Microbe"},{"key":"8293_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7150\/thno\/v01p0018","volume":"1","author":"L Zhu","year":"2011","unstructured":"Zhu L, et al. Real-time video imaging of protease expression in vivo. Theranostics. 2011;1:18\u201327.","journal-title":"Theranostics"},{"issue":"4","key":"8293_CR30","doi-asserted-by":"publisher","first-page":"e0123781","DOI":"10.1371\/journal.pone.0123781","volume":"10","author":"Y Liu","year":"2015","unstructured":"Liu Y, et al. Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2\/9 by Blocking NF-\u03baB and ERK\/MAPK Signaling Pathways. PLoS ONE. 2015;10(4):e0123781.","journal-title":"PLoS ONE"},{"issue":"2","key":"8293_CR31","first-page":"Ra32","volume":"15","author":"A Jezierska","year":"2009","unstructured":"Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009;15(2):Ra32\u201340.","journal-title":"Med Sci Monit"},{"issue":"1","key":"8293_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12885-021-07860-2","volume":"21","author":"H Jiang","year":"2021","unstructured":"Jiang H, Li H. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21(1):149.","journal-title":"BMC Cancer"},{"issue":"6","key":"8293_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","volume":"32","author":"A Russ","year":"2018","unstructured":"Russ A, et al. Blocking don\u2019t eat me signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review. Blood Rev. 2018;32(6):480\u20139.","journal-title":"Blood Rev"},{"issue":"2","key":"8293_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"key":"8293_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang W, et al. Advances in Anti-Tumor Treatments Targeting the CD47\/SIRP\u03b1 Axis. Front Immunol. 2020;11:18.","journal-title":"Front Immunol"},{"key":"8293_CR36","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.2147\/OTT.S249822","volume":"13","author":"Q Lu","year":"2020","unstructured":"Lu Q, et al. Potential New Cancer Immunotherapy: Anti-CD47-SIRP\u03b1 Antibodies. Onco Targets Ther. 2020;13:9323\u201331.","journal-title":"Onco Targets Ther"},{"key":"8293_CR37","doi-asserted-by":"publisher","first-page":"p9435030","DOI":"10.1155\/2020\/9435030","volume":"2020","author":"R Catal\u00e1n","year":"2020","unstructured":"Catal\u00e1n R, et al. CD47-SIRP\u03b1 Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer. J Immunol Res. 2020;2020:p9435030.","journal-title":"J Immunol Res"},{"key":"8293_CR38","doi-asserted-by":"crossref","unstructured":"Zhang H, et al. S216: CD47\/PD-L1 bispecific antibody (IBI322) in anti-PD-1 or PD-L1 treatment-resistant classical hodgkin lymphoma: a phase I study. HemaSphere. 2023;7(S3):e8102841.","DOI":"10.1097\/01.HS9.0000967776.81028.41"},{"issue":"3","key":"8293_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11523-025-01130-y","volume":"20","author":"C Eng","year":"2025","unstructured":"Eng C, et al. A Phase 1b\/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors. Target Oncol. 2025;20(3):519\u201330.","journal-title":"Target Oncol"},{"issue":"Supplement1","key":"8293_CR40","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1182\/blood-2019-122793","volume":"134","author":"Z Meng","year":"2019","unstructured":"Meng Z, et al. TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties. Blood. 2019;134(Supplement1):4063\u20134063.","journal-title":"Blood"},{"issue":"Supplement 1","key":"8293_CR41","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1182\/blood-2021-150606","volume":"138","author":"A Mehta","year":"2021","unstructured":"Mehta A, et al. Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin\u2019s Lymphoma: Initial Clinical Results. Blood. 2021;138(Supplement 1):3542\u20133542.","journal-title":"Blood"},{"issue":"1","key":"8293_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12967-023-04710-6","volume":"22","author":"T Wang","year":"2024","unstructured":"Wang T, et al. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile. J Transl Med. 2024;22(1):220.","journal-title":"J Transl Med"},{"issue":"1","key":"8293_CR43","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1097\/CAD.0000000000001229","volume":"33","author":"SJ Chen","year":"2022","unstructured":"Chen SJ, Bi YH, Zhang LH. Systematic analysis of the potential off-target activities of osimertinib by computational target fishing. Anticancer Drugs. 2022;33(1):e434\u201343.","journal-title":"Anticancer Drugs"},{"key":"8293_CR44","doi-asserted-by":"crossref","unstructured":"Chhouri H, Alexandre D, Grumolato L. Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer. Cancers (Basel). 2023;15(2).","DOI":"10.3390\/cancers15020504"},{"issue":"1","key":"8293_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","volume":"15","author":"M Babamohamadi","year":"2024","unstructured":"Babamohamadi M, et al. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis. 2024;15(1):17.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8293_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"issue":"Pt 2","key":"8293_CR47","doi-asserted-by":"publisher","first-page":"141003","DOI":"10.1016\/j.ijbiomac.2025.141003","volume":"305","author":"TY Liao","year":"2025","unstructured":"Liao TY, et al. Development of a tumor-region-selective activation monoclonal antibody targeting the 4-1BB receptor for enhanced therapeutic efficacy and safety. Int J Biol Macromol. 2025;305(Pt 2):141003.","journal-title":"Int J Biol Macromol"},{"issue":"Pt 4","key":"8293_CR48","doi-asserted-by":"publisher","first-page":"143176","DOI":"10.1016\/j.ijbiomac.2025.143176","volume":"309","author":"WH Lee","year":"2025","unstructured":"Lee WH, et al. Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy. Int J Biol Macromol. 2025;309(Pt 4):143176.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"8293_CR49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-020-00652-z","volume":"27","author":"WW Lin","year":"2020","unstructured":"Lin WW, et al. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci. 2020;27(1):76.","journal-title":"J Biomed Sci"},{"issue":"6","key":"8293_CR50","doi-asserted-by":"publisher","first-page":"e3000286","DOI":"10.1371\/journal.pbio.3000286","volume":"17","author":"YC Lu","year":"2019","unstructured":"Lu YC, et al. Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biol. 2019;17(6):e3000286.","journal-title":"PLoS Biol"},{"key":"8293_CR51","unstructured":"Huang B-C, et al. Spatial-hindrance-based pro-adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy. Bioeng Transl Med. n\/a(n\/a):e70015."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08293-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:02:35Z","timestamp":1787054555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08293-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8293"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08293-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1060"}}